Eisai halted Phase 3 development of lorcaserin for Dravet syndrome due to recruitment challenges. The drug was previously ...

AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...

Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...

EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...

Trump's HHS nominee Robert F. Kennedy Jr., an anti-vaccine advocate calling for stricter pharma oversight, contrasts with ...

Eyenovia halted Phase 3 trial of atropine-based myopia treatment after data showed it wouldn't meet primary endpoint. CEO ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Eli Lil­ly is now the sec­ond drug­mak­er to pro­pose a re­bate mod­el for 340B drug price dis­counts — and the sec­ond to ...

The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...

Adaptimmune Therapeutics announces 33% workforce reduction and restructuring to save $300 million through 2028. Company halts ...

ALX Oncology has found a new chief medical officer, tapping Alan Sandler for the role. Sandler comes to ALX from Mirati, ...

Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was ...